Recombinant Human EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2)

What is EMR2 and what is its basic molecular classification?

EMR2 (also known as ADGRE2) is a human myeloid-restricted adhesion G protein-coupled receptor (aGPCR) that belongs to group II GPCRs and is functionally included in the family of brain angiogenesis inhibitor molecules (BAIs) . EMR2 is highly homologous to F4/80, a widely acknowledged surface marker that defines murine tissue macrophages . As a typical aGPCR, EMR2 undergoes autoproteolytic processing at the extracellular GPCR proteolysis site (GPS) and is expressed as a bipartite complex containing the extracellular N-terminal fragment (NTF) and the seven-transmembrane (7TM) C-terminal fragment (CTF) .

What is the domain structure of EMR2 and how can it be modeled?

EMR2 contains multiple epidermal growth factor (EGF)-like modules in its extracellular domain (ECD) . Structural analysis using GPCRDB, DOMAC, and SCRATCH programs reveals that EMR2 is composed of five distinct domains :

• First domain: Modeled using templates including EGF domain with barium (PDB ID: 2BO2)

• Second domain: Similar to the first domain

• Third domain: Modeled with human notch-1 ligand binding protein (PDB ID: 1TOZ_A)

• Fourth domain: Shows good DOPE score (35.88)

• Fifth domain: Composed of EGF-TM7 helices

Ramachandran plot analysis of EMR2 domains showed that 72%-90% of residues fell within the most favored regions, 3%-31% in additionally allowed regions, and 2%-14% in generously allowed regions .

Where is EMR2 primarily expressed in human tissues?

EMR2 expression is myeloid-restricted, with expression primarily in:

• Monocytes/macrophages

• Neutrophils

• Myeloid dendritic cells (DCs)

The strongest in vivo EMR2 protein expression is detected in CD16+ blood monocytes and BDCA-3+ myeloid DCs . Additionally, foamy macrophages in atherosclerotic vessels and splenic Gaucher cells exhibit high EMR2 positivity, whereas multiple sclerosis brain foam cells express little if any EMR2 .

How is EMR2 expression regulated during macrophage differentiation?

EMR2 serves as a novel surface marker of human macrophage differentiation. Research shows that:

• EMR2 expression is persistently upregulated during in vitro differentiation of PMA-treated THP-1 cells into macrophage-like cells

• The upregulated EMR2 expression levels correlate closely with macrophage phenotypic markers (CD4, CD9, CD11b, and CD81)

• EMR2 protein expression increases during in vitro differentiation of macrophages but decreases following dendritic cell maturation

This dynamic expression pattern suggests a regulatory role of EMR2 in myeloid cell function and differentiation.

What methodologies can be used to assess EMR2 expression in patient samples?

Several methodological approaches can be employed to assess EMR2 expression:

• Flow cytometry analysis: Using antibodies like the EMR2-specific 2A1 monoclonal antibody to detect surface expression on different cell populations

• Western blotting: To assess protein expression levels in cell lysates

• Quantitative PCR: For evaluation of EMR2 transcript levels

• Immunohistochemistry: For tissue-specific expression patterns

For clinical samples, flow cytometry has been particularly useful in identifying EMR2 as a neutrophil biomarker in conditions like systemic inflammatory response syndrome (SIRS) and liver cirrhosis .

What are the primary signaling pathways activated by EMR2 in myeloid cells?

EMR2 activation triggers multiple signaling cascades:

What experimental approaches can be used to study EMR2-mediated signaling in vitro?

Researchers can employ several experimental approaches to study EMR2 signaling:

• Receptor activation studies:

  • Use of receptor-specific monoclonal antibodies (e.g., 2A1 mAb) to bind and ligate EMR2

  • Immobilized vs. soluble antibody comparison to evaluate functional differences

• Signaling inhibitor analysis:

  • PI3K inhibitors (Wortmannin, LY294002)

  • MAPK/ERK kinase inhibitors (PD98059, U0126)

  • JNK inhibitor (SP600125)

  • p38 inhibitor (SB203580)

  • PLC inhibitors (U73122)

• Phosphorylation analysis:

  • Western blotting to detect phosphorylation of signaling molecules (ERK, JNK, Akt)

  • Time-course and dose-dependent studies

• siRNA knockdown experiments:

  • Silencing EMR2 or downstream signaling molecules (e.g., Gα16) to confirm specificity

• Functional readouts:

  • Cytokine/chemokine production (IL-8, TNF-α)

  • Matrix metalloproteinase expression (MMP-9)

  • Cell morphology and differentiation markers

How is EMR2 implicated in inflammatory conditions?

EMR2 plays significant roles in several inflammatory conditions:

What is the role of EMR2 in brain tumors, particularly gliomas?

EMR2 has several important implications in glioma biology:

• Expression in glioma tissues: EMR2 is expressed in various histologic grades of gliomas .

• Association with PI3K pathway: Both EMR2 and PI3K are upregulated in glioblastoma after bevacizumab therapy. The PI3K-Akt pathway is involved in tumorigenesis, and upregulation of EMR2 may in turn upregulate PI3K, leading to increased tumor invasiveness .

• Correlation with tumor characteristics: Overexpression of EMR2 is associated with:

  • Mesenchymal glioblastoma subtype

  • Tumor invasiveness

  • Poor patient survival rates

  • Higher tumor grade

• Role in tumor biology: EMR2 regulates neutrophil function by producing reactive oxygen species (ROS) and degranulation, which may contribute to the tumor microenvironment .

• Potential therapeutic target: Research has explored approaches such as:

  • Stimulation of microglia and monocytes to inhibit tumor-initiating cells by down-regulating the EMR2 gene

  • Development of antibodies against EMR2

How can researchers effectively study EMR2 activation and its downstream effects?

Researchers can employ several advanced methodologies to study EMR2 activation:

• Cell models:

  • THP-1 human monocytic cell line for differentiation studies

  • Primary human monocytes/macrophages for validation

  • Neutrophil isolation and activation assays

• Activation methods:

  • Immobilized vs. soluble antibody comparison (e.g., 2A1 mAb)

  • Natural ligand (dermatan sulfate) stimulation

  • Mechanical stimulation in combination with ligands (especially for vibratory urticaria studies)

• Readout systems:

  • Quantitative analysis of pro-inflammatory mediators (ELISA, qPCR)

  • Western blotting for signaling molecule phosphorylation

  • Flow cytometry for surface marker expression

  • Functional assays (chemotaxis, phagocytosis, ROS production)

  • Inflammasome activation (IL-1β processing, caspase-1 activation)

• Statistical analysis:

  • Student's t-test for comparing differences between groups

  • Setting significance at p < 0.05, with asterisks indicating levels of significance (* p < 0.05, ** p < 0.01, *** p < 0.001)

What are potential approaches for targeting EMR2 for therapeutic purposes?

Several potential therapeutic approaches targeting EMR2 have been suggested:

• Antibody-based therapies:

  • Development of antibodies against EMR2 that can modulate its function

  • Targeting specific domains of EMR2 to affect ligand binding or receptor activation

• Small molecule inhibitors:

  • Designing competitive EMR2 inhibitors based on structure, function, and ligand binding sites

  • Targeting the Gα16 coupling or downstream signaling components like PLC or PI3K pathways

• Gene modulation approaches:

  • siRNA or CRISPR-based downregulation of EMR2 in specific cell types

  • Modulation of EMR2 expression to affect myeloid cell differentiation and function

• Targeting EMR2-ligand interactions:

  • Focusing on the residue Arg241, which is responsible for interaction with glycosaminoglycan and chondroitin sulfate

  • Developing molecules that mimic or block these interactions

What are the key considerations for accurately measuring EMR2 expression in clinical samples?

Researchers should consider several factors when measuring EMR2 expression:

• Sample processing time: EMR2 expression may be affected by the time between sample collection and processing, potentially leading to activation of myeloid cells ex vivo.

• Cell isolation methods: Different isolation protocols may affect the activation status of myeloid cells and consequently EMR2 expression.

• Antibody selection: Using validated antibodies with appropriate controls is crucial for accurate measurement.

• Measurement techniques: Flow cytometry is preferred for cellular expression studies, but immunohistochemistry may be necessary for tissue samples .

• Data interpretation challenges:

  • Electronic medical records (EMRs) may contain measurement errors and misclassifications

  • Validation studies may be needed, using manual chart abstraction or alternative data sources

  • Loss to follow-up can introduce bias in longitudinal studies

How should researchers approach contradictory findings in EMR2 research?

When confronted with contradictory findings, researchers should:

• Examine experimental conditions:

  • Differences in cell types used (THP-1 cells vs. primary cells)

  • Variations in activation methods (immobilized vs. soluble antibodies)

  • Differences in readout systems or time points

• Consider context-dependent effects:

  • EMR2 activation alone may have different effects compared to activation in the presence of other stimuli

  • The priming effect of EMR2 on neutrophil activation should be taken into account

• Analyze data quality issues:

  • Data discrepancies may arise from unstandardized data collection and documentation practices

  • Improperly matched data elements or variability in data vocabulary and definitions may contribute to contradictory findings

• Validation approaches:

  • Cross-validate findings using multiple methodologies

  • Perform rigorous statistical analysis, including sensitivity analyses

  • Consider using validation studies with gold standard data when possible

What are the key unanswered questions about EMR2 function and biology?

Several important questions remain unanswered:

• Structural determinants of EMR2 function:

  • How do specific domains contribute to receptor activation and signaling?

  • What is the molecular mechanism of EMR2 activation by mechanical forces?

• Signaling network integration:

  • How does EMR2-mediated signaling interact with other pathways in different contexts?

  • What are the cell type-specific differences in EMR2 signaling?

• Physiological roles:

  • What is the physiological function of EMR2 in tissue-resident macrophages?

  • How does EMR2 contribute to innate immune responses against pathogens?

• Disease mechanisms:

  • How does EMR2 dysfunction contribute to inflammatory disorders beyond vibratory urticaria?

  • What is the role of EMR2 in cancer progression and metastasis?

What emerging technologies might advance EMR2 research?

Several emerging technologies hold promise for advancing EMR2 research:

• Single-cell analysis:

  • Single-cell RNA sequencing to identify cell-specific expression patterns

  • Mass cytometry for high-dimensional analysis of EMR2+ cell populations

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize EMR2 localization and interactions

  • Live-cell imaging to study EMR2 dynamics during cellular activation

• CRISPR-based approaches:

  • Gene editing to create specific EMR2 variants

  • CRISPR screens to identify EMR2 interaction partners and regulators

• Computational modeling:

  • Molecular dynamics simulations of EMR2 structure and interactions

  • Systems biology approaches to integrate EMR2 into cellular signaling networks

• Organoid and advanced 3D culture systems:

  • Study EMR2 function in more physiologically relevant contexts

  • Examine EMR2 in tissue-specific microenvironments